P0924: Efficacy and Safety Assessment of Ustekinumab in Postoperative Crohn's Disease Patients in ChinaECCO'25Year: 2025
Authors: Xianzong, M.(1)*;Jia, Y.(2);Linyan, Z.(3); Xinmei, Z.(4); Xingzhao, H.(4); Ling, L.(5);Xuchun , Z.(5);Feng, T.(3);
(1)The First Medical Center of Chinese PLA General Hospital, Senior Department of Gastroenterology, Beijing, China;(2)The Seventh Medical Center of Chinese PLA General Hospital, Department of Gastroenterology, Beijing, China;(3)Shengjing Hospital of China Medical University, Department of Gastroenterology, Shenyang, China;(4)Nanfang Hospital- Southern Medical University, Guangdong Provincial Key Laboratory of Gastroenterology- Institute of Gastroenterology of Guangdong Province- Department of Gastroenterology, Guangzhou, China;(5)The First Affiliated Hospital of Chongqing Medical University, Department of Gastroenterology, Chongqing, China;
Torres J, Bonovas S, Doherty G, et al. ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. J Crohns Colitis. 2020. 14(1): 4-22.
P0925: Risk of postoperative Crohn’s disease recurrence in patients smoking e-cigarettes and heat-not-burn tobacco products: a multicenter retrospective studyECCO'25Year: 2025
Authors: ParigiMD, T.L.(1)*;Nardone, O.M.(2);Lisa, M.(3);Gabbiadini, R.(4);innocenti, T.(5);Bertani, L.(6);Allocca, M.(1);D'Amico, F.(1);Furfaro, F.(1);Zilli, A.(1);Castiglione, F.(7);Dragoni, G.(5);Fiorino, G.(8);Armuzzi, A.(9);Danese, S.(1);
(1)IRCCS Ospedale San Raffaele, Gastroenterology and Endoscopy, Milan, Italy;(2)University of Naples Federico II, Department of Clinical Medicine and Surgery, Naples, Italy;(3)University Vita-Salute San Raffaele, Division of Immunology- Transplantation and Infectious Disease, Milan, Italy;(4)IRCCS Humanitas Research Hospital, Department of Gastroenterology, Milan, Italy;(5)University of Florence, Department of Experimental and Clinical Biomedical Sciences, Florence, Italy;(6)ASL Toscana Nord- Ospedale di Pontedera, Gastroenterology, Pontedera PI, Italy;(7)University of Naples Federico II, Gastroenterology- Department of Clinical Medicine and Surgery, Naples, Italy;(8)San Camillo-Forlanini Hospital, Department of Gastroenterology & Digestive Endoscopy, Rome, Italy;(9)IRCCS Humanitas Research Hospital, Gastroenterology, Milan, Italy;
P0926: The impact of anti-integrin αvβ6 antibody positivity on clinical characteristics and treatment outcomes with biological agents in pediatric IBD: a single-center retrospective studyECCO'25Year: 2025
Authors: Oue, H.(1,2)*;Takeuchi, I.(1);Hiejima, E.(2);Tanioka, A.(1);Komorizono, R.(1);Maeda, Y.(2);Nihira, H.(2);Shiokawa, M.(3);Shimizu, H.(1);Arai, K.(1);
(1)National Center for Child Health and Development, Center for Pediatric Inflammatory Bowel Disease- Division of Gastroenterology, Tokyo, Japan;(2)Kyoto University Hospital, Department of Pediatrics, Kyoto, Japan;(3)Kyoto University Hospital, Department of Gastroenterology and Hepatology, Kyoto, Japan;
P0927: Surgery as a Treatment Option for CD: A Nationwide Cohort StudyECCO'25Year: 2025
Authors: Faye, A.(1)*;Axelrad, J.(2);Sun, J.(3);Halfvarson, J.(4);Soderling, J.(5);Olen, O.(6);Ludvigsson, J.(7);
(1)NYU Grossman School of Medicine, Department of Medicine/Division of Gastroenterology & Hepatology, New York City, United States;(2)NYU Grossman School of Medicine, Dept. of Medicine- Division of Gastroenterology & Hepatology, New York, United States;(3)Karolinska Institute, Epidemiology, Stockholm, Sweden;(4)Orebro, Medicine/Division of Gastroenterology & Hepatology, Orebro, Sweden;(5)Karolinska Institute, Epidemiology, Stockholm, United States;(6)Karolinska Institute, Medicine & Epidemiology, Stockholm, Sweden;(7)Karolinska, Epidemiology/Medicine, Stockholm, Sweden;
P0928: Patient endotypes in ulcerative colitis revealed by longitudinal symptom trajectories under therapyECCO'25Year: 2025
Authors: El Houjjaji, C.(1)*;Paun, A.(1);McBride, J.(2);Schreiber, S.(3);Mueller-Breckenridge, A.J.(1);
(1)Roche, Cardiovascular & Metabolism and Immunology CMI- Roche Pharmaceutical Research and Early Development pRED Systems Biology group, Basel, Switzerland;(2)Genentech, Research and Early Development, South San Francisco, United States;(3)Institute for Clinical Molecular Biology and Department of Medicine I, Kiel university- University Hospital Schleswig Holstein, Kiel, Germany;
P0929: Design and rationale for the phase 1c study evaluating the pharmacodynamic (PD) effects of vixarelimab in patients with Ulcerative Colitis (UC)ECCO'25Year: 2025
Authors: Neighbors, M.(1)*;Hains, A.(2);Rhee, H.(2);Tang, F.(3);Onabajo, O.(1);Quintanilla, L.(1);Eshghi, S.(1);Kulkarni, P.(4);Chatterjee, S.(5);Schroeder, A.(1);Garma, H.(6);Lear, S.(1);Hendricks, A.(7);Jha, D.(8);Mehandru, S.(8);
(1)Genentech- Inc., Translational Medicine Omni-Biomarker Development, South San Francisco, United States;(2)Genentech- Inc., gRED Early Clinical Development, South San Francisco, United States;(3)Genentech- Inc., Clinical Pharmacology, South San Francisco, United States;(4)Genentech- Inc., Cellular and Tissue Genomics, Cellular and Tissue Genomics, United States;(5)Genentech- Inc., Cellular and Tissue Genomics, South San Francisco, United States;(6)Genentech- Inc., Translational Medicine, South San Francisco, United States;(7)Genentech- Inc., Translational Medicine - Operations Diagnostics Technology Innovation, South San Francisco, United States;(8)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;
1 Jairath et al. Cochrane Database Syst Rev. 2017;9:CD011572.
P0930: Adalimumab is equally efficient as infliximab in achieving sustained remission in Ulcerative Colitis but inferior in patients with severe diseaseECCO'25Year: 2025
Authors: Gunnarsson, J.(1)*;Mavroudis, G.(2);Ågren, S.(2);Lasson, A.(3);de Lange, T.(4,5);Jonefjäll, B.(4);
(1)Sahlgrenska University Hospital/Sahlgrenska Hospital, Department of Gastroenterology and Hepatology, Gothenburg, Sweden;(2)Sahlgrenska University Hospital/Östra Hospital, Department of Medicine, Gothenburg, Sweden;(3)Södra Älvsborgs Hospital, Department of Medicine, Borås, Sweden;(4)Sahlgrenska University Hospital/Mölndals Hospital, Department of Medicine, Mölndal, Sweden;(5)University of Gothenburg, Department of Molecular and Clinical Medicine, Gothenburg, Sweden;
- Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther. 2018 Feb;47(4):454-465.
- Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis. Clin Gastroenterol Hepatol. 2020 Sep;18(10):2179-2191.
- Sandborn WJ, Sakuraba A, Wang A et al. Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States. Curr Med Res Opin. 2016 Jul;32(7):1233-41.
- Pouillon L, Baumann C, Rousseau H et al. Treatment Persistence of Infliximab Versus Adalimumab in Ulcerative Colitis: A 16-Year Single-Center Experience. Inflamm Bowel Dis. 2019 Apr 11;25(5):945-954.
P0931: Induction treatment with upadacitinib is associated with high rate of clinical response in patients with refractory Inflammatory Bowel DiseaseECCO'25Year: 2025
Authors: Kitsou, V.(1)*;Ioannou, A.(2);Kokkotis, G.(1);Chalakatevaki, K.(1);Laoudi, E.(1);Leonidakis, G.(2);Michopoulos, S.(2);Zampeli, E.(2);Bamias, G.(1);
(1)Sotiria Hospital, GI Unit, Athens, Greece;(2)Alexandra General Hospital, Department of Gastroenterology, Athens, Greece;
P0933: Symptoms improvement after VAAFT procedure in patients with perianal Crohn’s diseaseECCO'25Year: 2025
Authors: Andreotti, E.(1);Todeschini, A.(2)*;Geccherle, A.(2);Variola, A.(2);Cracco, N.(1);Orlandi, S.(2);Barugola, G.(1);
(1)IRCCS Sacro Cuore Don Calabria Hospital, Department of General Surgery, Negrar di Valpolicella, Italy;(2)IRCCS Sacro Cuore Don Calabria Hospital, IBD Unit, Negrar di Valpolicella, Italy;
P0935: A systematic review and quality assessment of clinical practice nursing guidelines for ostomy careECCO'25Year: 2025
Authors: Hutton, M.(1);Prins, H.(2);Yuan, Y.(2,3)*;Solitano, V.(3,4);Radford, S.(5);Vuyyuru, S.K.(3,6);Rieder, F.(7,8,9);Jairath , V.(2,3,6);
(1)London Health Sciences Centre, Nursing Practice Excellence and Innovation, London, Canada;(2)London Health Sciences Centre, Department of Medicine, London, Canada;(3)Western University, Department of Medicine, London, Canada;(4)Università Vita-Salute San Raffaele, Division of Gastroenterology and Gastrointestinal Endoscopy- IRCCS Ospedale San Raffaele, Milan, Italy;(5)The University of Nottingham- School of Medicine, NIHR Nottingham Biomedical Research Centre- Liver and GI Disorders, Nottingham, United Kingdom;(6)Alimentiv Inc., Gastroenterology, London, Canada;(7)Digestive Diseases Institute- Cleveland Clinic Foundation, Department of Gastroenterology- Hepatology and Nutrition, Cleveland, United States;(8)Cleveland Clinic Foundation, Program for Global Translational Inflammatory Bowel Diseases, Cleveland, United States;(9)Lerner Research Institute- Cleveland Clinic Foundation, Department of Cancer Biology, Cleveland, United States;
P0936: Switch from intravenous to subcutaneous infliximab: first subcutaneous dose and cumulative area under curve.ECCO'25Year: 2025
Authors: Padulles-Zamora, N.(1);Cleries Rovira, P.(2);Alonso Moreno, M.(2)*;Rodriguez Moranta, F.(3);Ruiz Cerulla, A.(3);Rodriguez Alonso, L.(3);Muñoz Bolaño, M.(2);Guardiola Capon, J.(3);
(1)Hospital Universitari de Bellvitge. IDIBELL, Pharmacy, Barcelona, Spain;(2)Hospital Universitari de Bellvitge, Pharmacy, Barcelona, Spain;(3)Hospital Universitari de Bellvitge, Gastroenterology, Barcelona, Spain;
References
1. Roblin X et al., Higher serum infliximab concentrations following subcutaneous dosing are associated with deep remission in patients with inflammatory bowel disease. J Crohns Colitis. 2023 Nov 2:jjad188.
2. Schreiber S et al., Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease. Gastroenterology. 2021;160(7):2340-2353
P0937: Role of Interleukin-8 in Predicting Long-Term Response to Vedolizumab in Ulcerative Colitis PatientsECCO'25Year: 2025
Authors: Mínguez, A.(1)*;Ripoll, P.(1);Argumánez, V.(1);Navarrete, I.(1);Aguerri, A.(2);Garrido, A.(1);Aguas, M.(1);Iborra, M.(1);Cerrillo, E.(1);Bastida, G.(1);Nos , P.(1);
(1)La Fe University and Polytechnic Hospital, Gastroenterology Department, Valencia, Spain;(2)La Fe University and Polytechnic Hospital, IIS Hospital la Fe. IBD research group, Valencia, Spain;
1. Soendergaard C, Seidelin JB, Steenholdt C, Nielsen OH. Putative biomarkers of vedolizumab resistance and underlying inflammatory pathways involved in IBD. BMJ Open Gastroenterol. 2018 May 31;5(1):e000208. doi: 10.1136/bmjgast-2018-000208
2. Cotton JA, Platnich JM, Muruve DA, Jijon H, Buret AG, Beck PL. Interleukin-8 in gastrointestinal inflammation and malignancy: induction and clinical consequences. International Journal of Interferon, Cytokine and Mediator Research. 2016;8:13-34https://doi.org/10.2147/IJICMR.S63682
3. Grimm MC, Elsbury SK, Pavli P, Doe WF. Interleukin 8: cells of origin in inflammatory bowel disease. Gut. 1996 Jan;38(1):90-8. doi: 10.1136/gut.38.1.90
4. Bazzichetto C, Milella M, Zampiva I, Simionato F, Amoreo CA, Buglioni S, Pacelli C, Le Pera L, Colombo T, Bria E, Zeuli M, Del Bufalo D, Sperduti I, Conciatori F. Interleukin-8 in Colorectal Cancer: A Systematic Review and Meta-Analysis of Its Potential Role as a Prognostic Biomarker. Biomedicines. 2022 Oct 19;10(10):2631. doi: 10.3390/biomedicines10102631.
5. Nielsen OH, Rüdiger N, Gaustadnes M, Horn T. Intestinal interleukin-8 concentration and gene expression in inflammatory bowel disease. Scand J Gastroenterol. 1997 Oct;32(10):1028-34. doi: 10.3109/00365529709011220.
6. Bertani L, Caviglia GP, Antonioli L, Pellicano R, Fagoonee S, Astegiano M, Saracco GM, Bugianesi E, Blandizzi C, Costa F, Ribaldone DG. Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases. J Clin Med. 2020 May 2;9(5):1323. doi: 10.3390/jcm9051323.
P0938: Corticosteroid and opiate use in Inflammatory Bowel Disease, 25 years after the Crohn's Therapy, Resource, Evaluation, and Assessment Tool (TREAT) registry was establishedECCO'25Year: 2025
Authors: Pinnuck, B.(1)*;Su, W.K.(2,3,4);Wilson, W.(5);Pipicella, J.(3,6,7);Wark, G.(4);Archdiacono, M.(8);Walker, G.(9,10,11);Forbes, A.(12);Su, H.(13);Schultz, M.(14);Lawrance, I.(15,16);Dutt, S.(17,18);Brett, L.(19);Lynch, K.(1,20);Connor, S.J.(3,4,21,22);Andrews, J.M.(20,23,24);
(1)Royal Adelaide Hospital, Gastroenterology and Hepatology, Adelaide, Australia;(2)Crohn’s Colitis Cure, Research, Sydney, Australia;(3)The Ingham Institute for Applied Medical Research, Gastroenterology- Hepatology and Inflammatory Bowel Disease Research Group, Sydney, Australia;(4)Liverpool Hospital, Gastroenterology and Hepatology, Sydney, Australia;(5)South Australia Health, South Australia Health, Adelaide, Australia;(6)Crohn's Colitis Cure, Head of Operations, Sydney, Australia;(7)University of New South Wales, South West Sydney Clinical School, Sydney, Australia;(8)St Vincent’s Hospital Sydney, Pharmacy, Sydney, Australia;(9)Royal Brisbane and Women's Hospital, Gastroenterology and Hepatology, Brisbane, Australia;(10)QIMR Berghofer, Gastroenterology, Brisbane, Australia;(11)University of Queensland, Faculty of Medicine, Brisbane, Australia;(12)University of Otago, Department of Medicine, Christchurch, New Zealand;(13)Te Whatu Ora Health, Gastroenterology, Christchurch, New Zealand;(14)University of Otago, Department of Medicine, Dunedin, New Zealand;(15)Saint John of God Subiaco, Centre for Inflammatory Bowel Disease, Perth, Australia;(16)University of Western Australia, School of Medicine and Pharmacology, Perth, Australia;(17)The Children’s Hospital at Westmead, Gastroenterology, Sydney, Australia;(18)The University of Sydney, Sydney School of Medicine Faculty of Medicine and Health, Sydney, Australia;(19)Logan Hospital, Gastroenterology, Brisbane, Australia;(20)University of Adelaide, Faculty of Health Sciences, Adelaide, Australia;(21)Crohn’s Colitis Cure, Board member, Sydney, Australia;(22)University of New South Wales, South West Sydney Clinical Campuses, Sydney, Australia;(23)Crohn’s Colitis Cure, Board member, Adelaide, Australia;(24)Central Adelaide Local Health Network, Gastroenterology and Hepatology, Adelaide, Australia;
P0939: Efficacy of Ustekinumab-based integrated medicine therapy in patients with symptomatic stricturing Crohn's disease: a retrospective studyECCO'25Year: 2025
Authors: Liu, J.(1)*;Hu, W.(2);Li, S.(3);Hu, S.(1);Chen, Y.(1);
(1)the Second Affiliated Hospital of Zhejiang University School of Medicine, Department of Gastroenterology, Hangzhou, China;(2)the First Affiliated Hospital of Zhejiang Chinese Medical University, Gastroenterology Department, Hangzhou, China;(3)the Second Affiliated Hospital- Zhejiang University School of Medicine, Department of Nursing, Hangzhou, China;
1.Bharadwaj S, Fleshner P, Shen B. Therapeutic Armamentarium for Stricturing Crohn's Disease: Medical Versus Endoscopic Versus Surgical Approaches. Inflammatory bowel diseases 2015; 21(9): 2194-213.
2.Bouhnik Y, Carbonnel F, Laharie D, et al. Efficacy of adalimumab in patients with Crohn&’s disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study. Gut 2018; 67(1): 53.
3.Zorzi F, Zuzzi S, Onali S, et al. Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study. Alimentary Pharmacology & Therapeutics 2012; 35(12): 1397-407.
4.Lin S-N, Mao R, Qian C, et al. Development of antifibrotic therapy for stricturing Crohn’s disease: lessons from randomized trials in other fibrotic diseases. 2022; 102(2): 605-52.
5.Murate K, Nakamura M, Yamamura T, et al. Ustekinumab is effective against small bowel lesions in Crohn’s disease: two case reports. Clinical Journal of Gastroenterology 2021; 14(1): 129-35.
6.Elmoursi A, Barrett TA, Perry C. Double Biologic Therapy for Refractory Stricturing Crohn’s Disease: A Successful Case of Deep Remission with Ustekinumab and Vedolizumab. Inflammatory bowel diseases 2020; 26(7): e62-e3.
P0940: Patient perspectives from a real-world adalimumab biosimilar switching programECCO'25Year: 2025
Authors: Choon, X.Y.(1)*;Moore, A.(2);Sharma, E.(1);Anderson, S.(1);Gecse, K.(1);Mawdsley, J.(1);Ray, S.(1);Dart, R.(1);Irving, P.(1);Samaan, M.(1);
(1)Guy's and St Thomas' NHS Foundation Trust, Gastroenterology, London, United Kingdom;(2)Chelsea and Westminster Hospital NHS Foundation Trust, Gastroenterology, London, United Kingdom;
1. Abitbol V, Benkhalifa S, Habauzit C, Marotte H. Navigating adalimumab biosimilars: an expert opinion. J Comp Eff Res. 2023 Nov;12(11):e230117. doi: 10.57264/cer-2023-0117. Epub 2023 Oct 19. Erratum in: J Comp Eff Res. 2024 Feb;13(2):e240003c1. doi: 10.57264/cer-2024-0003c1. PMID: 37855223; PMCID: PMC10690439.
2. A C Moore, D Russell, R Dart, S Dias, S Ghuman, B Petri, E Sharma, S Ray, S Anderson, J Mawdsley, P M Irving, M A Samaan, P411 Stable pharmacokinetics and biochemical markers of inflammatory bowel disease activity: Results from a real-world adalimumab biosimilar switching program, Journal of Crohn's and Colitis, Volume 16, Issue Supplement_1, January 2022, Pages i401–i402, https://doi.org/10.1093/ecco-jcc/jjab232.538
P0941: Questionnaire survey of Japanese patients with inflammatory bowel disease and physicians on shared decision making in advanced therapy: A web-based PAIR surveyECCO'25Year: 2025
Authors: Imai, K.(1)*;Hirai, F.(2);Matsumoto, T.(3);Goda, Y.(1);Fujimitsu, Y.(1);Kajioka, T.(1);Oiwa, M.(1);Honjo , T.(1);Higashikawa, M.(4);Ueno, M.(1);
(1)EA Pharma Co.- Ltd., IBD Strategy, Tokyo, Japan;(2)Fukuoka University, Gastroenterology, Fukuoka, Japan;(3)Iwate Medical University, Gastroenterology, Morioka, Japan;(4)EA Pharma Co.- Ltd., Pharmaceutical Development- Development Promotion & Data Science Group, Tokyo, Japan;
P0942: Orismilast for the treatment of moderate to severe Ulcerative Colitis: Analysis of preliminary data from UCORIS, a phase 2a, open-label, single-arm exploratory clinical trialECCO'25Year: 2025
Authors: Velte Honoré, T.(1)*;Bendtsen, F.(1);Seidelin, J.B.(2);Burisch, J.(1);
(1)Copenhagen University Hospital - Amager and Hvidovre, Gastro Unit- Medical Section, Hvidovre, Denmark;(2)University Hospital of Copenhagen - Rigshospitalet, Department of Medical Gastroenterology, Copenhagen, Denmark; Copenhagen IBD Center
1. Zhao M, Sall Jensen M, Knudsen T, et al. Trends in the use of biologicals and their treatment outcomes among patients with inflammatory bowel diseases – a Danish nationwide cohort study. Aliment Pharmacol Ther. 2022;55(5):541-557. doi:10.1111/apt.16723
2. Li H, Zhang Y, Liu M, et al. Targeting PDE4 as a promising therapeutic strategy in chronic ulcerative colitis through modulating mucosal homeostasis. Acta Pharm Sin B. 2022;12(1):228-245. doi:10.1016/j.apsb.2021.04.007
P0943: Estimated benefits and willingness of remote monitoring in IBD patients under maintenance therapy – ATTENDANT studyECCO'25Year: 2025
Authors: Brams, S.(1)*;Beeckmans, D.(1);Delen, S.(2);Fierens, L.(3);Vanhaverbeke, M.(3);Sabino, J.(4);Verstockt, B.(4);Vermeire, S.(4);Ferrante, M.(4);
(1)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(2)ZOL Maas en Kempen, Department of Gastroenterology and Hepatology, Maaseik, Belgium;(3)KU Leuven, Department of Chronic Diseases and Metabolism, Leuven, Belgium;(4)University Hospitals Leuven- KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;
P0944: Fluorescently labelled adalimumab to visualise drug targeting in Inflammatory Bowel Disease: a safety, feasibility and dose-finding study.ECCO'25Year: 2025
Authors: Van Dijken, R.(1,2)*;Volkmer, P.(1);Huizinga, H.(1,2);Aledlbi, N.(1);Gabriels, R.(1);Robinson, D.(1,3);Gorpas, D.(4);Visschedijk, M.(1);Lub-de Hooge, M.(2);Nagengast, W.(1);
(1)University Medical Center Groningen, Gastroenterology and Hepatology, Groningen, The Netherlands;(2)University Medical Center Groningen, Clinical Pharmacy and Pharmacology, Groningen, The Netherlands;(3)Erasmus MC, Otorhinolaryngology and Head and Neck Surgery, Rotterdam, The Netherlands;(4)Helmholtz Zentrum München, Institute of Biological and Medical Imaging, München, Germany;
